ETD 001
Alternative Names: ETD-001Latest Information Update: 03 Oct 2024
Price :
$50 *
At a glance
- Originator Enterprise Therapeutics
- Class Antiasthmatics; Antifibrotics
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 26 Sep 2024 The US FDA grants rare paediatric disease designation (RPDD) to ETD 001 for treatment of Cystic fibrosis
- 28 Jul 2024 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in United Kingdom (Inhalation)
- 30 Jan 2024 Enterprise Therapeutics plans a phase IIa trial for Cystic fibrosis (Inhalation)